GlykoGen aims to develop a pipeline of anti-glycan antibodies to target specific, currently ‘hard to treat’ cancers, including pancreatic cancer, using an innovative and patentable process. GlykoGen’s vision is the delivery of more effective, less-invasive/destructive therapies for cancer, targeting cancer cells through their surface glycans. Glycans are of interest in the study of cancer because they play a role in almost every biological process and are involved in every major disease. However, their role in cancer is not yet well explored, due to the difficulties of producing antibodies to glycans.